Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:50:50.487Z.
Calculation as of: 2026-10-06T18:50:50.487Z.
Quote observation: 2026-10-06T18:49:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7114033928f702054061c44125c31231f02474951b0017c983a2cfe9aac3c1c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Cibus, Inc.
Market Cap
$121.37M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Cibus, Inc. (CBUS) | $121.37M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.28M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.21M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.34M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.54M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.06M | N/A |
| BGM Group Ltd. (BGM)vs › | $117.61M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.61M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
